Showing results (31-40 of 203) with videos related to
Sort By:
Pageof 21
Pharmacotherapy|November 26, 2008
Comparison of opioid requirements and analgesic response in opioid-tolerant versus opioid-naïve patients after total knee arthroplastyAsad E Patanwala, Donna L Jarzyna, Michael D Miller, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2014
Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110)Danielle P Porter, Rima Kulkarni, Todd Fralich, et al.AIDS (London, England)|June 6, 2008
Genetic basis of variation in tenofovir drug susceptibility in HIV-1Robert J Murray, Fraser I Lewis, Michael D Miller, et al.Antimicrobial Agents and Chemotherapy|August 6, 2014
The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitroRima Kulkarni, Rebecca Hluhanich, Damian M McColl, et al.Antimicrobial Agents and Chemotherapy|November 19, 2014
A cell-based strategy to assess intrinsic inhibition efficiencies of HIV-1 reverse transcriptase inhibitorsMichael E Abram, Manuel Tsiang, Kirsten L White, et al.Antimicrobial Agents and Chemotherapy|September 25, 2004
Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitroWilliam E Delaney, Huiling Yang, Michael D Miller, et al.Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|April 9, 2018
Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeksNicolas Margot, Stephanie Cox, Moupali Das, et al.Journal of Clinical Microbiology|July 28, 2012
Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapyEvguenia S Svarovskaia, Ross Martin, John G McHutchison, et al.Journal of Virology|September 13, 2003
Nef does not affect the efficiency of human immunodeficiency virus type 1 fusion with target cellsMinoru Tobiume, Janet E Lineberger, Christopher A Lundquist, et al.Antiviral Therapy|January 12, 2017
Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarateNicolas Margot, Stephanie Cox, Moupali Das, et al.Pageof 21